-
公开(公告)号：US5116951A
公开(公告)日：1992-05-26
申请号：US585229
申请日：1990-09-19
IPC分类号： C07K14/705 , A61K38/00 , C07K1/00 , C07K14/00 , C07K14/715 , C12P21/00 , G01N33/53
CPC分类号： C07K14/7155 , A61K38/00
摘要： The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 94 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
摘要翻译： 本发明涉及基本上纯的白介素9受体分子及其用途。 作为白细胞介素-9抑制剂的使用，可以列举作为白细胞介素-9的测定用诊断剂，作为药物的筛选剂。 白细胞介素-9受体的特征在于约94千道尔顿的糖蛋白，其在用N-糖苷酶F消化后产生约54千道尔顿的肽。
-
公开(公告)号：US5180678A
公开(公告)日：1993-01-19
申请号：US832192
申请日：1992-02-06
IPC分类号： C07K14/705 , A61K38/00 , C07K1/00 , C07K14/00 , C07K14/715 , C12P21/00 , G01N33/53
CPC分类号： C07K14/7155 , A61K38/00
摘要： The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 64 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
-
3.发明授权Method for inhibiting production of IGE and method for enhancing production of IGG using interleukin 9 and inhibitors thereof 失效用于抑制IGE生产的方法和使用白介素9及其抑制剂增强IGG生产的方法
公开(公告)号：US5132109A
公开(公告)日：1992-07-21
申请号：US593238
申请日：1990-10-05
申请人： Bernard Dugas , Catherine Druez , Pierre Braquet , Jean M. Mencia-Huerta , Catherine Uyttenhove , Jean-Christophe Renauld , Jacques Van Snick
发明人： Bernard Dugas , Catherine Druez , Pierre Braquet , Jean M. Mencia-Huerta , Catherine Uyttenhove , Jean-Christophe Renauld , Jacques Van Snick
IPC分类号： A61K38/00 , A61K38/17 , A61K38/20 , A61K39/395 , A61K45/00 , A61P37/00 , A61P37/04 , A61P37/06 , A61P43/00 , C07K14/54 , C07K14/715 , C07K16/24 , C12N5/08 , C12P21/02
CPC分类号： C07K16/247 , A61K38/2026 , A61K38/2033 , C07K14/7155 , C07K16/244 , A61K38/00
摘要： A method for inhibiting production of IgE, and a method for enhancing production of IgG are taught. The methods are linked to the role of interleukin 9 in antibody production. Specifically, production of IgG is potentiated by administering either to a subject or a cell culture a combination of interleukin 4 and interleukin 9. Production of IgE is inhibited by administering an amount of an interleukin 9 inhibitor to a subject.
摘要翻译： 教导了抑制IgE产生的方法以及增强IgG产生的方法。 该方法与抗体生产中白细胞介素9的作用有关。 具体地，通过向受试者或细胞培养物施用白细胞介素4和白介素9的组合来增强IgG的产生。通过向受试者施用一定量的白介素9抑制剂来抑制IgE的产生。
-
公开(公告)号：US5246701A
公开(公告)日：1993-09-21
申请号：US807260
申请日：1991-12-13
申请人： Bernard Dugas , Catherine Druez , Pierre Braquet , Jean M. Mencia-Huerta , Catherine Uyttenhove , Jean-Christophe Renauld , Jacques Van Snick
发明人： Bernard Dugas , Catherine Druez , Pierre Braquet , Jean M. Mencia-Huerta , Catherine Uyttenhove , Jean-Christophe Renauld , Jacques Van Snick
IPC分类号： A61K38/00 , A61K38/17 , A61K38/20 , C07K14/715 , C07K16/24
CPC分类号： C07K16/247 , C07K14/7155 , C07K16/244 , A61K38/00 , Y10S424/805
摘要： A method for inhibiting production of IgE, and a method for enhancing production of IgG are taught. The methods are linked to the role of interleukin 9 in antibody production. Specifically, production of IgG is potentiated by administering either to a subject or a cell culture a combination of interleukin 4 and interleukin 9. Production of IgE is inhibited by administering an amount of an interleukin 9 inhibitor to a subject.
摘要翻译： 教导了抑制IgE产生的方法以及增强IgG产生的方法。 该方法与抗体生产中白细胞介素9的作用有关。 具体地，通过向受试者或细胞培养物施用白细胞介素4和白介素9的组合来增强IgG的产生。通过向受试者施用一定量的白介素9抑制剂来抑制IgE的产生。
-
公开(公告)号：US5164317A
公开(公告)日：1992-11-17
申请号：US799011
申请日：1991-11-25
IPC分类号： A61K38/00 , C07K14/54 , C12N5/0787
CPC分类号： C12N5/0642 , C07K14/5425 , A61K38/00 , C12N2501/23
摘要： The glycoprotein known as P40, characterized by a molecular weight of from about 30 to 40 kilodaltons and an isoelectric point of about 10, previously recognized as a helper T cell growth factor, also enhances growth and proliferation of mast cells and their maintenance viability and differentation status in vitro.
摘要翻译： 称为P40的糖蛋白，其特征在于分子量为约30至40千道尔顿，等电点为约10，先前被认为是辅助T细胞生长因子，也增强了肥大细胞的生长和增殖及其维持活力和分化 体外状态
-
6.发明申请Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases 审中-公开包含il-12或il-23的疫苗用于治疗自身免疫性疾病公开(公告)号：US20070048261A1
公开(公告)日：2007-03-01
申请号：US10582810
申请日：2004-12-14
CPC分类号： A61K39/0008 , A61K2039/55555 , A61K2039/55566 , A61K2039/55577
摘要： The present invention provides improved vaccines and immunogenic compositions comprising IL-12 or IL-23, and processes for the preparation of such vaccines and immunogenic compositions.
摘要翻译： 本发明提供改进的疫苗和包含IL-12或IL-23的免疫原性组合物，以及制备这种疫苗和免疫原性组合物的方法。
-
公开(公告)号：US5208218A
公开(公告)日：1993-05-04
申请号：US246482
申请日：1988-09-19
IPC分类号： G01N33/53 , A61K38/00 , A61K39/395 , A61P37/00 , A61P37/04 , C07H21/00 , C07H21/04 , C07K1/20 , C07K9/00 , C07K14/00 , C07K14/435 , C07K14/47 , C07K14/475 , C07K14/52 , C07K14/54 , C07K16/00 , C07K16/22 , C07K16/24 , C07K19/00 , C12N1/21 , C12N15/09 , C12N15/24 , C12P21/02 , C12P21/08 , C12R1/91 , G01N33/577
CPC分类号： C07K14/5425 , C07K16/244 , A61K38/00 , Y10S530/808 , Y10S930/14 , Y10S930/141
摘要： The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports interleukin 2- and interleukin 4-independent growth of helper T cells. Even more particularly, the present invention relates to the helper T cell growth factor P40, pharmaceutical compositions thereof and antibodies thereto. The present invention also contemplates a method for inducing the proliferation of helper T cells. The helper T cell growth factor contemplated herein is useful in the stimulation of specific cells in the immune system.
-
公开(公告)号：US10035851B2
公开(公告)日：2018-07-31
申请号：US15341077
申请日：2016-11-02
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
-
公开(公告)号：US20170137507A1
公开(公告)日：2017-05-18
申请号：US15341077
申请日：2016-11-02
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
-
公开(公告)号：US07371383B2
公开(公告)日：2008-05-13
申请号：US10412703
申请日：2003-04-11
申请人： Jennifer Lynne Reed , William Dall'Acqua , Jacques Van Snick , Jean-Christophe Renauld , Francoise Cormont , Catherine Uyttenhove
发明人： Jennifer Lynne Reed , William Dall'Acqua , Jacques Van Snick , Jean-Christophe Renauld , Francoise Cormont , Catherine Uyttenhove
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76
摘要： The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.
摘要翻译： 本申请描述了中和嵌合和人源化抗人IL-9抗体，以及其用于鉴定人IL-9上的中和表位以及用于预防和治疗哮喘，支气管高反应性，特应性变态反应和其它相关疾病的药物。 特别公开的是衍生自以下鉴定的三种鼠抗人IL-9抗体作为MH9A3，MH9D1和MH9L1的重组抗体。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.023 秒)
